Pamplona Therapeutics

Pioneering Next-Generation Therapeutics:
AI Meets Protein Degradation
Redefining Medicine view more

SCROLL DOWN

Who We Are ?

Pamplona is dedicated to improving human health
by addressing unmet clinical needs.

Founded in 2022, Pamplona Therapeutics is an innovative drug research and development company committed to tackling significant unmet medical needs and advancing global health.

Pamplona Therapeutics utilizes its proprietary ASTRIDE^® algorithm platform, which is built on protein structure and Al technology, to accelerate the design of novel therapeutics. Leveraging targeted protein degradation technology, we are committed to developing best-in-class and first-in-class innovative drugs for oncology and autoimmune diseases.

Vision

Transform healthcare through groundbreaking innovation

Mission Statement

Develop safe and effective therapeutics to improve patients' lives

Our Pipeline

Our R&D pipeline is strategically focused on high-impact therapeutic areas, including autoimmune diseases and oncology, with substantial market potential and distinct competitive advantages.

We have advanced our core program, P001, to identify multiple preclinical candidates showing strong in vitro and in vivo performance across several indications, including potential first-in-class and best-in-class molecules.

Newsroom view more

Pamplona Therapeutics and Coherent Biopharma Enter Strategic Collaboration to Advance AI-Designed Degrader–Conjugate Therapeutics

Pamplona Therapeutics and Coherent Biopharma today announced a strategic collaboration to combine Pamplona's AI-driven targeted protein degradation (TPD) molecular design capabilities with Coherent's dual-target conjugation technologies, Bi-XDC and C-PROTAC.

Mar 12, 2026

Pamplona Therapeutics Receives FDA Clearance of IND Application for First-in-Class IRAK4 Degrader

Pamplona Therapeutics today announced that its first-in-class targeted protein degrader for the treatment of autoimmune diseases has received clearance from the U.S. Food and Drug Administration (FDA).

Dec 29, 2025